Key facts
- Semarion’s last known valuation is $39.6M (Mar 2025).
- It has raised $7.0M; the latest was Later Stage VC ($3.8M) in Mar 2025.
- Notable investors include The FSE Group, Parkwalk Advisors, Cambridge Enterprise Ventures, Oxford Innovation Finance, Cambridge Capital Group — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Semarion
- ·The full record, as it builds
Funding rounds
No funding rounds for Semarion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Semarion
Developer of a drug discovery and cell microcarrier platform designed to revolutionize adherent cell screening. The company's platform leverages novel materials physics to provide microcarriers that function as ultra-miniaturized, magnetically steerable wells, carrying small colonies of cells to enable more powerful assay workflows and new experimental paradigms, allowing researchers to focus on advancing novel drugs for unmet medical needs.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2018
- Employees
- 10
- Website
- semarion.com/
- Ownership
- Privately Held (backing)
Semarion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Semarion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Semarion in its N-PORT filings yet. We sweep new filings monthly.